- Home
- ZLAB vs PTGX Comparison
ZLAB vs PTGX Comparison
Compare ZLAB & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- PTGX
- Stock Information
- Founded
- ZLAB 2013
- PTGX 2006
- Country
- ZLAB China
- PTGX United States
- Employees
- ZLAB N/A
- PTGX N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- ZLAB Health Care
- PTGX Health Care
- Exchange
- ZLAB Nasdaq
- PTGX Nasdaq
- Market Cap
- ZLAB 3.6B
- PTGX 3.3B
- IPO Year
- ZLAB 2017
- PTGX 2016
- Fundamental
- Price
- ZLAB $36.40
- PTGX $51.25
- Analyst Decision
- ZLAB Buy
- PTGX Strong Buy
- Analyst Count
- ZLAB 5
- PTGX 9
- Target Price
- ZLAB $54.28
- PTGX $67.11
- AVG Volume (30 Days)
- ZLAB 886.5K
- PTGX 1.0M
- Earning Date
- ZLAB 08-05-2025
- PTGX 08-05-2025
- Dividend Yield
- ZLAB N/A
- PTGX N/A
- EPS Growth
- ZLAB N/A
- PTGX N/A
- EPS
- ZLAB N/A
- PTGX 0.86
- Revenue
- ZLAB $418,326,000.00
- PTGX $207,801,000.00
- Revenue This Year
- ZLAB $44.07
- PTGX N/A
- Revenue Next Year
- ZLAB $49.13
- PTGX $47.15
- P/E Ratio
- ZLAB N/A
- PTGX $59.19
- Revenue Growth
- ZLAB 43.72
- PTGX N/A
- 52 Week Low
- ZLAB $16.01
- PTGX $32.50
- 52 Week High
- ZLAB $44.34
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- ZLAB 52.67
- PTGX 45.80
- Support Level
- ZLAB $34.79
- PTGX $49.86
- Resistance Level
- ZLAB $36.73
- PTGX $57.24
- Average True Range (ATR)
- ZLAB 1.23
- PTGX 2.06
- MACD
- ZLAB -0.46
- PTGX -0.78
- Stochastic Oscillator
- ZLAB 25.91
- PTGX 16.14
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.